Granules India Limited posted a net profit of Rs 31 crore for the second quarter ended September 30, 2015, an increase of 40 per cent over Rs 22 crore registered during the corresponding quarter last year.

The company logged a revenues of Rs 366 crore during the second quarter, an increase of 19 per cent over Rs 308 crore registered during the corresponding quarter last year.

The company stated that its operating margin improved by 204 basis point to 19.2 per cent from 17.2 per cent.

Giving a business break up for the second quarter on a consolidated basis, the company stated that Active Pharmaceutical Ingredients (APIs) contributed 44 per cent, Pharmaceutical Formulation Intermediaries (PFIs) 27 per cent and Finished Dosages 29 per cent. Geography-wise, the regulated markets contributed 55 per cent and the rest of the world 45 per cent.

C Krishna Prasad, Chairman and Managing Director of Granules India, in a statement said, “Our continuous endeavour to improve operational efficiency and process innovation has resulted yet another strong quarter for us. We remain focussed on strengthening our core businesses, developing a differentiated product basket through API division and increasing our global footprints by capitalising the strategic efforts.”

The company’s standalone sales during the quarter were Rs 333 croe, an increase of 22 per cent over the same quarter previous year. The EBIDTA and PAT stood at Rs 64 crore and Rs 27 crore respectively during the second quarter, reflecting an increase of 14 per cent and 3 per cent.

The board of directors approved payment of second interim dividend of 15 paise per share of face value of Rs 1 each for the financial year 2015-16.

Related Topics
comment COMMENT NOW